None listed
Conditions
Interventions
Drug : In both group, 0.05mg/kg intravenous midazolam was initially administered. In etomidate group, 0.05 mg/kg (0.025 mL/kg) bolus injection of etomidate (Etomidate lipuro, 20 mg/10 mL/A, BBraun Kor
s consciousness was assessed if the Modified Observer'
s Assessment of Alertness / Sedation (MOAAS) was>
3 points. In propofol group, 0.05 mg/kg (0.025 mL/kg) bolus injection of propofol (Freefol-MCT, 120 mg/12 mL, Daewon Pharm. Co., Ltd., Seoul, Korea) was initially administered. As with etomidate, if t
3 points to maintain appropriate sedation, after at least 60 seconds of observation, additional injections were required.
Sponsors
Korea University Anam Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients between the ages of more than 20 years old from American Society of Anesthesiologists (ASA ?to ? )were scheduled to undergo endoscopy including colonoscopy, polypectomy and endoscopic submucosal dissection were included in this study.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had known or suspected (1) a history of adverse events with prior sedation; (2) known hypersensitivity to egg products, soy beans, etomidate, and propofol (3) known adrenocortical insufficiency, chronic corticoid therapy, or porphyria; (4) pregnant or breastfeeding; (5) desire to undergo endoscopy without sedation; (6) inability to provide informed consent. If there was hemodynamic instability (systolic pressure < 90 mmHg or oxygen saturation (Sp02) was 90% in room air or <95% with 2L/min oxygen) at baseline measurement before procedure, the patient was withdrawn from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiopulmonary adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| Risky adverse event | — |
Countries
Korea, Republic of
Contacts
Public ContactJung Min Lee
Korea University Anam Hospital
Outcome results
None listed